基于Granada-Ⅱ分类法评价利伐沙班用于非瓣膜性心房颤动药物相关问题

Evaluation of Drug-Related Problems of Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Based on Granada-Ⅱ Classification Method

目的探讨利伐沙班用于非瓣膜性心房颤动(简称房颤)患者的药物相关问题(DRPs),以促进临床合理使用。方法抽取医院心内科2022年1月至10月使用利伐沙班的非瓣膜性房颤住院患者的病历127份,以利伐沙班药品说明书为基础,参考相关指南、共识和文献,采用Granada-Ⅱ分类法对患者使用利伐沙班的必要性(包括DRP1和DRP2)、有效性(包括DRP3和DRP4)、安全性(包括DRP5和DRP6)进行评价。结果共纳入127例使用利伐沙班的非瓣膜性房颤患者,其中55例(43.31%)发生了DRPs,包括46例(36.22%)DRP4,7例(5.51%)DRP5,2例(1.57%)DRP6。结论该院心内科非瓣膜性房颤患者使用利伐沙班的DRPs主要为有效性问题。需加强合理用药培训及干预,促进利伐沙班在非瓣膜性房颤患者中的合理使用。

Objective To investigate the drug-related problems(DRPs)of rivaroxaban in patients with non-valvular atrial fibrillation(AF),and to promote the rational use of rivaroxaban in the clinic.Methods A total of 127 medical records of inpatients with non-valvular atrial fibrillation treated with rivaroxaban in the Department of Cardiology in the hospital from January to October 2022 were selected.Based on the drug manual of rivaroxaban,relevant guidelines,consensus,and literature,the GranadaⅡclassification method was used to evaluate the necessity(including DRP1 and DRP2),effectiveness(including DRP3 and DRP4),and safety(including DRP5 and DRP6)of using rivaroxaban in patients.Results A total of 127 patients with non-valvular atrial fibrillation treated with rivaroxaban were included,with 55 cases(43.31%)of DRPs,including 46 cases(36.22%)of DRP4,seven cases(5.51%)of DRP5,and two cases(1.57%)of DRP6.Conclusion DRPs of rivaroxaban in patients with non-valvular atrial fibrillation in the Department of Cardiology in the hospital are mainly the effectiveness.It is necessary to strengthen training and intervention on rational drug use to promote the rational use of rivaroxaban in patients with non-valvular atrial fibrillation.